Abstract
Follicular helper T-cell lymphomas (TFH lymphomas) were discussed in session V of the lymphoma workshop of the European Association for Haematopathology (EA4HP)/Society for Hematopathology (SH) 2022 meeting in Florence, Italy. The session focused on the morphologic spectrum of TFH lymphoma, including its three subtypes: angioimmunoblastic-type (AITL), follicular-type, and not otherwise specified (NOS). The submitted cases encompassed classic examples of TFH lymphoma and unusual cases such as those with early or indolent presentations, associated B-cell proliferations, or Hodgkin/Reed–Sternberg-like cells. The relationship between TFH lymphoma and clonal hematopoiesis was highlighted by several cases documenting divergent evolution of myeloid neoplasm and AITL from shared clonal mutations. The distinction between TFH lymphoma and peripheral T-cell lymphoma, not otherwise specified (PTCL, NOS), was stressed, and many challenging examples were presented. Various cases highlighted the difficulties of differentiating TFH lymphoma from other established types of lymphoma and reactive conditions. Cutaneous T-cell lymphoma expressing TFH markers, particularly when resulting in lymph node involvement, should be distinguished from TFH lymphomas. Additional immunophenotyping and next-generation sequencing studies were performed on various cases in this session, highlighting the importance of these technologies to our current understanding and classification of TFH lymphomas.
Similar content being viewed by others
Avoid common mistakes on your manuscript.
Introduction
T follicular helper (TFH) cells represent a functional subset of CD4-positive lymphocytes that are specialized providers of B-cell help. In normal immune responses, TFH cells are necessary for the formation and maintenance of germinal centers (GCs) and interact with GC B cells, aiding in their differentiation towards antibody-producing plasma cells and memory cells [1]. In 2007, immunophenotyping and gene expression profiling analyses identified the TFH cell as the cell of origin (COO) of angioimmunoblastic T-cell lymphoma (AITL) [2,3,4], and this specific cellular derivation has become a cardinal defining feature of the disease [5] Over time, other peripheral T-cell lymphomas (PTCLs) have been recognized to similarly express immunophenotypic markers (CD10, BCL6, CXCL13, PD1, and ICOS) and/or gene expression signatures characteristic of TFH cells [2,3,4, 6,7,8,9,10]. In the 2017 revised 4th WHO classification, an umbrella category of “nodal lymphomas of TFH origin” was created to include AITL, which remains the prototypic TFH lymphoma, and two related entities sharing TFH features, namely, follicular TCL and PTCL with TFH immunophenotype [11]. The concept of related entities unified by common clinical, immunophenotypic features has been reinforced by genetic findings [8, 12,13,14] and carried over to new classification schemes. The ICC-2022 recognizes follicular helper T-cell lymphoma as a single entity comprising three subtypes, angioimmunoblastic-type (AITL), follicular-type, and not otherwise specified (NOS) [15]. The proposed WHO5-2022 classification is slightly different, considering a family of three distinct nodal T-follicular helper cell lymphomas with similar suffixes, i.e., angioimmunoblastic-type, follicular-type, and NOS [16].
The central theme of the 2022 EA4HP/SH workshop in Florence was “Provisional and Emerging Disease Entities.” Forty-two cases were submitted for session V, dedicated to the topic “Lymphomas with TFH Phenotype.” Specifically, the call requested cases illustrating the borderlands of TFH lymphoma with PTCL, NOS and reactive conditions, and the association with clonal hematopoiesis (CH). The final diagnoses fell into three categories. Twenty-five cases represented examples of TFHL, 11 cases were concluded as other PTCL entities or lymphoproliferative disorders with TFH antigen expression, and six cases consisted of reactive or other lymphoproliferations.
Follicular helper T-cell lymphomas
The 25 cases ultimately classified as TFH lymphoma (TFHL) comprised 16 cases of AITL, 3 follicular-type (TFHL-F), and 6 NOS (TFHL-NOS) (Supplemental Table 1). The 25 patients with TFHL were 13 males and 12 females, with a median age of 68 years (range 30 to 80 years). Among 13 patients with detailed information on the presenting symptoms, interestingly, only one presented with a complete constellation of general symptoms and biological abnormalities classically reported in association with AITL. Seven patients presented with clinically silent disease, and the other five patients had various non-specific complaints [17, 18].
Except for one tonsillectomy, all submitted biopsies were from lymph nodes (LN). These comprised 19 surgical excisions and 5 core biopsies, reflecting increasing reliance on fast and minimally invasive small-volume biopsies for lymphoma diagnoses [19,20,21]. The submitted core biopsies were sufficient for diagnostic testing in all cases, including high-throughput sequencing (HTS) analyses performed in three cases. However, four patients with a final diagnosis of TFHL made on excision had one or several needle core biopsies preceding the contributive excisional biopsy. In two of these patients, the cores had led to an erroneous diagnosis (of Hodgkin lymphoma in one case and EBV-positive B-cell lymphoproliferative disorder in another case), and in two patients, the core biopsies were non-conclusive and likely delayed the diagnosis. Only one case with a core biopsy was submitted with unstained slides to the workshop, emphasizing how a lack or paucity of archived material from core biopsies precludes the possibility of tissue-based research and compromises potential future clinical needs [22].
Immunophenotypic features, EBV status, and clonality results of the 25 TFHL cases are summarized in Fig. 1. HTS analysis was performed in 22 cases either by the submitters (12 cases) or by the panel (10 cases) (Fig. 2A, Supplementary information and Supplementary Table 2). Several studies have highlighted the characteristic mutational landscape of TFH lymphomas, which typically associates mutations in epigenetic regulators (TET2, DNMT3A, and IDH2), RHOA G17V, and alterations in the T-cell receptor (TCR) signaling pathway [12, 23,24,25,26]. In this small cohort of workshop cases, TET2 was the most frequently mutated gene in 21 out of 24 cases, often with 2 or 3 mutations. RHOA mutation (G17V hotspot) was detected in 9 out of 22 cases, DNMT3A in 7 out of 25 cases, and only 3 out of 18 AITL harbored an IDH2 mutation involving the R172 residue.
The submitted TFHL cases were separated according to their most interesting feature(s) into thematic groups, which addressed the following: the clinical and pathological variety of AITL, the features of TFHL-F and TFHL-NOS, the spectrum of associated B-cell proliferations, and the association of TFH lymphomas with CH and myeloid neoplasms.
The clinicopathologic spectrum of AITL: partial nodal involvement, early phase, and asymptomatic disease
AITL remains the best-characterized subtype of TFH lymphoma, with distinctive clinical and pathological features [27]. AITL mainly affects elderly adults, with a median age of 65 years. Most patients present with generalized lymphadenopathy (> 80%) systemic symptoms (> 50%), and frequent cutaneous manifestations or involvement of other extranodal sites [28]. Laboratory abnormalities including anemia (often hemolytic and Coombs-positive), polyclonal hypergammaglobulinemia (30%), hypereosinophilia, cytopenia, and various autoantibodies are commonly observed [28,29,30]. Patients are usually treated with anthracycline-containing combination chemotherapy, and the outcome of the disease is dismal with overall survival rates in the range of 30–35% at 5 years [30]. Morphologically, AITL is composed of atypical medium-sized lymphocytes with often clear cytoplasm, increased vascularity, and a prominent polymorphous microenvironment with eosinophils, plasma cells, histiocytes, and large immunoblastic cells which may be Reed–Sternberg-like [28, 31] with expanded follicular dendritic cell (FDC) meshworks [31, 32]. Three histological patterns are described: pattern-I, with hyperplastic follicles; pattern-II, with regressive follicles; and pattern-III, diffuse, and which is the most commonly encountered [33, 34]. The neoplastic cells are usually CD4+ and show TFH marker expression [2, 33,34,35,36].
Three cases submitted to the workshop illustrated disseminated neoplasms with limited tumor burden in asymptomatic or pauci-symptomatic patients. Case LYWS-1232, presented by Pedro Farinha (Fig. 3A–L) was most remarkable since after a two-year follow-up without treatment, the patient remained asymptomatic. This 68-year-old woman presented first with localized inguinal adenopathy and a skin rash which resolved after the LN biopsy. Six months later, enlarging LN in several areas prompted another biopsy. Both surgically excised LN showed a preserved architecture comprised of numerous lymphoid follicles with often small, regressively transformed GCs surrounded by uniform but variably expanded mantle zones and fewer hyperplastic GCs. Immunostaining highlighted clusters of CD3+ CD4+ T cells strongly positive for PD1, ICOS, and CD10, and uniformly negative for CD7, confined to the outer edge of the follicles. Flow cytometry on the first biopsy found 3% of the total T cells with an aberrant sCD3- CD4+ CD7- immunophenotype. CD21 and CD23 showed preserved FDC meshworks confined to the follicles, and EBV was not detected. An identical T-cell clone was found in the two biopsies and HTS performed on the second specimen showed only one pathogenic mutation in TET2. This case elicited ample discussion regarding how to best diagnose this condition characterized by persistent and disseminated clonal TFH cells not identifiable by morphology alone, in an otherwise hyperplastic LN. Although interfollicular areas were not significantly expanded, with no conspicuous increased vessels, discrete clusters of extrafollicular slightly atypical cells were highlighted by ICOS and PD1. Therefore, the panel favored a diagnosis of AITL, best ascribed to pattern-I and pattern-II; although in this case, the observed features did not completely fit the original description of the different patterns. Indeed, instead of attenuated mantle zones usually reported in the pattern-I, the follicles in case LYWS-1232 had thick mantle zones, with the neoplastic cells distributed between the GCs and the inner aspect of the mantles. Cases LYWS-1248 submitted by Danielle Maracaja (Fig. 3M and N) and LYSW-1383 submitted by Mats Ehinger (Fig. 3O and P) were two other examples of AITL with low neoplastic cell burden and preserved nodal architecture showing the role of immunohistochemistry to highlight atypical TFH cells at the periphery of the GCs and in the interfollicular areas. These two cases also showed preserved, thick mantle zones in the involved follicles. On the contrary, case LYWS-1364 presented by Joan Somja, was more typical of AITL pattern-I. While also characterized by a subtle atypical infiltrate of clear TFH cells around hyperplastic GCs with attenuated mantle zones, the disease occurred in an elderly lady who had polyarthralgia, fever, hypergammaglobulinemia, diffuse lymphadenopathy, slight splenomegaly, and peripheral blood involvement detected by flow cytometry (0.1% circulating CD4+ CD10+ cells). The LN harbored monoclonal TR gene rearrangements, and by HTS mutations in TET2, DNMT3A, and RHOA G17V, the latter with only 1% variant allele frequency, confirming the low neoplastic cell content.
Other cases exemplified peculiar clinical features or context. Case LYWS-1435 submitted by Giorgio Croci was another example of indolent AITL. In that case, a first core biopsy had been diagnosed as an atypical lymphoproliferation and re-biopsy after four years without treatment showed histologically typical AITL with mutations in TET2, DNMT3A, and RHOA. In that case, it was not a question of limited tumor burden in the first biopsy, but rather poorly preserved morphology of what was clearly a lymphoma from the beginning, which remained clinically silent for several years. Case LYWS-1366 submitted by Birgitta Sander showed typical AITL histology, but the patient had no generalized symptoms and had reduced immunoglobulin levels. Case LYWS-1441 submitted by Pierre Isnard was an AITL diagnosed in a LN core biopsy in a 66-year-old man eleven years after a kidney transplant. Post-transplant lymphoproliferative disorders are rarely of T-cell type, and most commonly consist of PTCL, NOS or hepatosplenic T-cell lymphoma [37]. Despite the limited sampling, the typical features of AITL were present, including the expansion of FDCs and EBV-positive B-cell blasts. Pathogenic mutations in CD28, ARID1A, and SETD2 were identified (Fig. 4).
TFH lymphoma, follicular-type
The designation of this rare subtype of TFHL refers to a pattern of growth related to follicular structures, lacking the extrafollicular proliferation of FDC and proliferative high endothelial venules characteristic of AITL [9, 38, 39]. It was introduced in the 2008 WHO classification as a subtype of PTCL, NOS (follicular T-cell lymphoma), and was moved in 2016 to the category of nodal PTCL with TFH phenotype [5, 11]. TFHL-F encompasses two morphologic presentations: either a truly follicular pattern, mimicking follicular lymphoma (FL-like), or more commonly a pattern resembling progressive transformation of GCs (PTGC-like). In FL-like TFHL-F, the neoplastic cells feature variable cytomorphology, sometimes with clear cytoplasm, and form well-defined intrafollicular aggregates sustained by a meshwork of FDC. In PTGC-like TFHL-F, aggregates of medium-sized pale or clear atypical neoplastic T cells are distributed within expanded mantle zones in large nodules mainly composed of small IgD+ B cells. Besides the t(5;9)(q33;q22) ITK::SYK fusion rather specific to TFHL-F but present in only a minority of the cases [40], the mutational pattern of TFHL-F overlaps with that of AITL [8, 41].
Three cases of TFHL-F (LYWS-1096, 1144, and 1368) were submitted, two with a PTGC-like pattern, and one with FL-like features. The three cases comprised CD21/CD23+ FDC meshworks associated with follicles and CD4+ neoplastic cells that showed a strong TFH immunophenotype (Fig. 1). The three cases also contained CD30+ EBV-positive or CD30+ EBV-negative HRS-like B-cells. This has been reported in the literature as a source of potential diagnostic pitfall with classic Hodgkin lymphoma (cHL) or nodular lymphocyte predominant Hodgkin/B-cell lymphoma [9, 42,43,44]. Coexpression of CD30 by the neoplastic cells reported in 75% of one case series [44] was conspicuous in only one case (LYWS-1368). The PTCG-like case (Fig. 5A–G) presented by Emily Mason was diagnosed in a patient who had received BCG immunotherapy for bladder cancer and presented with inguinal lymphadenopathy. By staging, the disease was localized. HTS analysis showed two mutations in TET2 and RHOA G17V. The patient was treated by standard polychemotherapy and is alive with no evidence of disease after three years of follow-up. Data in the literature suggest that compared to AITL, TFHL-F more commonly presents as localized stage I/II disease [9, 45, 46]. Whether these might represent a subset of cases with a better prognosis requires further studies. The other two cases of TFHL-F (LYWS-1144 and LYWS-1096 submitted by A. Gray and Stefano Lazzi) presented as disseminated disease. Case LYWS-1096 (Fig. 5H–L) was a good example of the FL-like pattern; it comprised many tumor cells, positive for CD4 and strongly positive for TFH markers and negative for CD7. This case harbored pathogenic mutations in TET2 (2 mutations), CXCR4, CTTNB1, and VAV1, but no RHOA alteration.
TFH lymphoma, NOS
TFHL-NOS is the least well-defined subtype of TFHL. It encompasses CD4+ PTCLs expressing a TFH immunophenotype, defined by the expression of at least 2 and ideally 3 TFH markers out of a panel of at least five markers (CD10, BCL6, PD1, ICOS, and CXCL13) that are now recommended to be tested routinely and systematically, any time TFHL might enter into diagnostic consideration [15, 16]. TFHL-NOS may present some features overlapping with those characteristic of AITL, like the presence of EBV+/-B-cell blasts or some increased vascularity, but lacks the typical prominent inflammatory background, vascular proliferation, or FDC expansion of AITL [9, 38, 39].
Five cases were classified as TFHL-NOS (LYWS-1218, 1265, 1285, 1302, and 1411), four were diagnosed in LN and one in a tonsillectomy. In all cases, the neoplastic cells were CD4+ and expressed at least 2 and often more than 2 TFH markers (Fig. 1). Case LYWS-1302 (Fig. 6A–D) submitted by WH-W Lin was an example of TFHL-NOS with an abundant epithelioid cell content, lacked proliferation of FDCs and contained rare EBV-positive cells. It has been shown that a significant proportion of cases formerly classified as lymphoepitheloid PTCL, NOS (so-called Lennert lymphoma) represent CD4+ neoplasms characterized by a TFH phenotype and are best classified as TFHL [47]. In that case where HTS analysis failed due to insufficient DNA quality, standard cytogenetic analysis had shown an abnormal karyotype.
Case LYWS-1218 submitted by Marco Pizzi (Fig. 6E–L), occured in a 72-year-old patient who had sore throat and bilateral tonsillar enlargement. The tonsillectomy contained atrophic follicles separated by broad T-zones expanded by a monomorphic proliferation of medium-sized CD3+ CD4+ cells, showing little atypia and a strong TFH immunophenotype with minimal micro-environment. In addition, a sharply demarcated area negative for CD20 and CD3 consisted of mature plasma cells, positive for CD138, MUM-1, and IgG but negative for both light chains and for EBV. There was no FDC expansion, and the Ki67 proliferation index was extremely low in both plasma and T-cell compartments. Molecular studies showed monoclonal TRB and TRG, polyclonal IG (IGH, IGK, and IGL) gene rearrangements, and mutations in TET2, IRF8, NOTCH1, DNMT3A, VAV1, and TNFRSF14 (Fig. 2A and Supplemental Table 1). The case was submitted with the diagnosis of “indolent TFH proliferation” because the disease was localized by staging, and the patient is still doing very well after 1 year. Given the constellation of morphologic, phenotypic, and genetic findings, the panel favored a diagnosis of TFHL-NOS, acknowledging that a subset of those cases may follow an indolent clinical course or slow progression. Regarding the associated EBV-negative IgG+ light chain-negative polytypic plasma cell proliferation, in the absence of a systemic plasma cell neoplasm, a diagnosis of associated plasmacytoma was favored, given its sharp demarcation from the TFHL, and the lack of a plasma cell component admixed with the TFHL.
The spectrum of associated B-cell proliferations in TFH lymphoma
The presence of a large B-blastic component, infected or not with EBV, is a characteristic component of AITL, reflected in the name of the entity. These large B-cells, which morphologically may mimic HRS cells, are also often observed in other subtypes of TFHL and are a source of misdiagnosis as HL [42, 48]. Specifically, all three TFHL-F discussed above contained HRS-like cells. Another case of AITL (LYWS-1111 submitted by Joshua Menke) occurred in a patient who had been treated for “atypical HL” and presented with recurrent adenopathy. A microbiopsy of the recurrent LN was interpreted as recurrent cHL, followed by an excision that provided the definitive diagnosis of AITL containing relatively numerous EBV+ large cells. In retrospect, the feature unusual for cHL on the microbiopsy was the strong expression of B-cell markers (PAX5 and CD20) on the CD30+ HRS-like cells. More pronounced B-cell and/or plasma cell proliferations may be observed, polytypic or monotypic, and containing or not EBV, best characterized in AITL but also reported in TFHL-NOS. Transformations to diffuse large B-cell lymphoma in sequential biopsies are well described [32, 42, 49,50,51].
Prominent B-cell expansions may even obscure the underlying TFHL. Three such cases were submitted (LYWS-1080, 1137, and 1453). Case LYWS-1137 presented by Nives Zimmermann was a 30-year-old man with lymphadenopathy, fevers, pleural effusion, and rashes. The patient underwent two LN core biopsies, leading to a diagnosis of an EBV+ lymphoproliferative disorder, which was initially treated with rituximab, but he progressed under treatment. In a subsequent surgically excised LN (Fig. 7A–C), the histopathological features were typical of AITL, including FDC expansion and a proliferation of atypical CD3+ CD4+ T cells with clear cytoplasm expressing CD10, BCL6, and PD1. A component of EBV-positive large PAX5+ CD30+ B cells was present but not prominent, likely attenuated by the treatment. This case was particularly unusual because it occurred in a young adult at an age where a diagnosis of TFHL is unlikely, which must have contributed to missing the diagnosis compounded by the initially limited sampling. Mutations were found in RHOA (G17V), IDH2 (R172K), TET2 (two mutations), and STAT6 (variant of unknown significance), with variant allele frequencies in the range of 18 to 24%, suggesting that they were all somatic. Case LYWS-1080 submitted by Katrin Kurz (Fig. 7D–K), occurred in a more typical clinical setting in an 81-year-old woman with altered general condition, pleural effusions, generalized lymphadenopathy, and splenomegaly. The histological picture of the LN biopsy was dominated by a polymorphic infiltrate of large EBV+ B cells and monotypic EBV-kappa-positive plasmacytic cells. Clues to identification of the underlying AITL were the presence of arborizing high endothelial venules, expanded CD21+ FDCs and clusters of CD3+ CD4+ BCL6+ PD1+ ICOS+ atypical clear cells. PCR-based clonality studies showed an oligoclonal pattern for TR genes and monoclonal IG rearrangements. HTS found mutations typical of TFHL (TET2, DNMT3A, and IDH2 R172K), and no additional variants that could be ascribed specifically to a B-cell component. The consensus diagnosis was AITL with associated monoclonal EBV-positive lymphoplasmacytic proliferation. This designation was preferred over considering two independent diagnoses, i.e., AITL and B-cell lymphoma, because the two components were intermixed, and because B-cell expansions are considered part of the biology of TFHL, with a clonal relationship to the T-cell neoplasm due to shared mutations originating in clonal hematopoiesis having been formally demonstrated in several cases [49, 52,53,54].
Association of TFH lymphoma with clonal hematopoiesis (CH) and myeloid neoplasms
Up to 80% of patients with TFHL have underlying CH, with shared TET2 and/or DNMT3A mutations in the early progenitor cells (i.e., hematopoietic stem cells) as well as the lymphoma [55,56,57,58]. CH appears to be the source of the increased incidence of myeloid neoplasms after TFHL-directed therapy [56, 58, 59]. Several studies have shown that while TET2 and DNMT3A mutations are present in both myeloid and T-cell compartments, RHOA and IDH2 mutations appear confined to the neoplastic T cells [58, 60, 61], suggesting that additional mutations are needed for lymphomagenesis.
Five cases submitted to the workshop demonstrate this relationship between TFHL and CH or myeloid neoplasm. All patients with available HTS data demonstrated a shared TET2 mutation between the myeloid and lymphoid compartments. The T-cell diagnosis was AITL in four cases, and a clonal T-cell lymphoproliferation suspicious for a TFHL in one case. Case LYWS-1389 (Erica Swenson) had a concurrent diagnosis of myelodysplastic syndrome (MDS) and AITL with a shared TET2 mutation, and with DNMT3A and RHOA mutations additionally identified only in the AITL component involving the pleural fluid. Case LYWS-1156 (Yahya Al-Ghamdi) was a patient with clonal cytopenia of undetermined significance preceding a typical AITL. A small monoclonal B-cell population was also identified in the staging bone marrow biopsy, and a TET2 mutation was shared between the LN and bone marrow. While the bone marrow cells were not sorted for genetic analysis, it raises the question of whether the TET2 mutation was also shared by the B-cell clone, as described previously in AITL patients with TET2 mutations identified in microdissected B-cells from tissue sections [62]. Presented orally was LYWS-1247 by Natasha Lewis (Fig. 8A–M), which elegantly demonstrated the relationship between CH, AITL, and myeloid neoplasms. The patient showed shared TET2 and DNMT3A mutations in sorted neoplastic T-cells and bulk peripheral blood, with RHOA p.G17V and IDH2 p.R172K mutations in the AITL cells. The bone marrow biopsy did not show morphologic evidence of a myeloid neoplasm at diagnosis. After chemotherapy for AITL, the patient developed new cytopenias, due to a therapy-related myeloid neoplasm (MDS with excess blasts—2, WHO4R-2017), with the same TET2 and DNMT3A mutations previously identified, and with the acquisition of additional abnormalities in RUNX1 p.D198N and CEBPA p.H260N.
Other T-cell lymphoma entities or other lymphoproliferative disorders
Peripheral T-cell lymphoma, NOS
PTCL, NOS is a mature T-cell lymphoma that does not meet the criteria for any other specific entity. GEP studies have identified two molecular subgroups within PTCL, NOS that resemble Th2 and Th1 cell differentiation profiles, known as PTCL-GATA3 and PTCL-TBX21, respectively. These subgroups have demonstrated differences in their morphological, molecular, and clinical characteristics [10, 63,64,65]. The lymphoepithelioid variant of PTCL, NOS (Lennert lymphoma) is characterized by the abundance of often clustered epithelioid histiocytes intermingled with neoplastic cells reportedly derived from CD8+ cytotoxic T cells [66, 67]. Over time, PTCLs with Lennert-like morphology were identified with overlapping features of AITL or with varying CD4+ or CD8+ immunophenotypes [68, 69]. Studies that have re-evaluated lymphoepithelioid PTCLs using a set of TFH markers revealed many, but not all, of them to be within the spectrum of TFHL [47, 70, 71], indicating that Lennert-like morphology can be seen in TFHL.
The boundary between PTCL, NOS and TFH, NOS is currently established based on the expression of a minimum two TFH markers. However, some series have reported that 20–30% of PTCL-NOS cases may express a single TFH marker [10, 72, 73] and the significance of this limited expression has yet to be fully investigated. Additionally, there are similar mutations in epigenetic regulators (such as TET2 and DNMT3A) in cases of PTCL, NOS, particularly in the PTCL-TBX21 subgroup, which includes a subset with a cytotoxic phenotype [74, 75]. The availability of HTS studies and a comprehensive panel of TFH markers in the workshop cases can provide further insights into the boundaries between TFH-NOS and PTCL, NOS and enhance our understanding of the usefulness of mutational profiles in distinguishing between these entities [76].
Six cases submitted as “PTCL with expression of TFH markers or TFH immunophenotype,” were ultimately reclassified by the panel as PTCL, NOS. Three of these cases had lymphoepithelioid features. LYWS-1061 submitted by Megan Fitzpatrick (Fig. 9A–E) lacked sufficient TFH marker expression (only CD4 and ICOS) to diagnose TFH lymphoma. LYWS-1313 (Luis Colomo) was difficult but we could not unambiguously identify a neoplastic population convincingly positive for TFH markers (Supplemental Table 3). The third case with Lennert-like features (LYWS-1191, Siok-Bian Ng) was an unusual relapse of a PTCL, NOS with cytotoxic molecule expression at diagnosis and a background with many TFH cells. Moreover, none of these cases contained mutations characteristic of TFH lymphoma (Supplemental Table 2).
Presented orally by Lianne Koens, LYWS-1401 was an unusual PTCL with AITL-like histology, including clear cells with mixed inflammation, arborizing blood vessels, and prominently distorted follicular dendritic cell meshworks (Fig. 9F–L). The tumor cells were CD8+, and despite ICOS, BCL-6, and partial PD1 expression, this conflicted with the proposed COO of TFHL and, thus, is considered not diagnostic of AITL, Additionally, the constellation of mutations in this case (STAT3, NOTCH2, VAV1, TBL1XR1, and CSF3R) is not typical for TFHL (Supplemental Table 2) and a diagnosis of PTCL, NOS with features of AITL was favored. Interestingly, potentially activating mutations in the intracellular domain of NOTCH2 were additionally found in two other PTCL, NOS described above, (LYWS-1313 LYWS-1061) both of which showed Th1-differentiation/PTCL-TBX21 by the immunohistochemical algorithm [65].
The last two cases in this subsection fulfilled the criteria for PTCL, NOS, despite each demonstrating positivity for two TFH markers. Case LYWS-1393 (Samah Kohla) demonstrated large cell cytology, loss of many T-cell antigens including CD4 and CD8, and no CD30 expression. The tumor was cytotoxic (perforin+) with coexpression of PD1 and BCL6. Case LYWS-1398 (Saumyaranjan Mallick) consisted of multiple large, extranodal tumoral masses weakly positive for CD4 with a partial TFH phenotype (PD1 and weak BCL6). The morphologic features and clinical presentation were inconsistent with a diagnosis of one of the recognized subtypes of TFHL. These two cases caution that the expression of two TFH markers should be in the context of a CD4+ phenotype and that additional more specific criteria may be required to establish a diagnosis of TFHL [36].
Cutaneous T-cell lymphoma (CTCL)
CTCL with LN involvement is critical to distinguish from other subtypes of PTCL since management and treatment protocols differ substantially [77]. Mycosis fungoides (MF) and other primary CTCL frequently derive from the CD4+ T-helper subsets. A strong association with TFH immunophenotype has been previously demonstrated in the majority of cases of MF [78] and in primary cutaneous CD4+ small/medium lymphoproliferative disorder, in which positivity of up to 3 TFH markers was demonstrated in 92% of cases [79]. That said, AITL can involve the skin, and expression of TFH markers and detection of RHOA p.G17V and IDH2 p.R172K mutations in this context can suggest the differential diagnosis if staging information is not yet available [80]. Three cases submitted to the workshop as nodal TFHL were re-classified as primary CTCL with secondary LN involvement. The LNs LYWS-1174 (Yi Zhou) and LYWS-1349 (Gorana Gasljevic) were each preceded by a history of MF. The LN morphology showed non-specific effacement by intermediate to large-sized T cells with clear cytoplasm (LYWS-1174) or effacement by dermatopathic areas (LYWS-1349). CD4+ neoplastic cells in both cases expressed three TFH markers (PD1+ and ICOS+, plus BCL6 or CXCL13). Interestingly, case LYWS-1174 harbored a TP63 rearrangement, which has been previously described in other PTCLs including ALK-negative anaplastic large-cell lymphoma, PTCL, NOS, and transformed MF (Fig. 10A–H) [81, 82]. The panel considered this case to represent secondary nodal involvement by transformed MF. Case LYWS-1349 demonstrated composite mantle cell lymphoma, together with nodal involvement by CTCL. LYWS-1263 (Bei Yang) submitted as TFHL involved a 74-year-old female with fatigue, weight loss, splenomegaly, and extensive lymphadenopathy. She also had a diffuse rash, WBC count of 22.7 × 109/L, negative HTLV1 serology, and rapidly progressive, fatal disease. The LN demonstrated interfollicular lymphoid infiltrates of hyperchromatic cells with convoluted nuclei and nucleoli, positive for CD4, PD1, BCL-6, ICOS, and TP53. HTS found mutations in TP53 c.733G>A (22% VAF) and CCR4 c.971dup (17% VAF). While it is difficult to know with certainty, the pattern of infiltration, probable leukemic involvement, and mutational profile are most consistent with a CTCL with leukemic presentation, such as Sézary syndrome.
Adult T-cell leukemia/lymphoma (ATLL)
ATLL has a myriad of clinical presentations and can mimic several subtypes of PTCL, including harboring TFH immunophenotype or AITL-like features [83]. To avoid misdiagnosis, it is crucial to perform systematic HTLV1 serology, particularly in areas where the HTLV1 virus is endemic. Adrien Pecriaux presented case LYWS-1359, which involved a 62-year-old man of Caribbean ancestry with high-stage lymphadenopathy and splenomegaly. An inguinal LN biopsy appeared as a tumor-cell-rich AITL, with abundant lymphoma cells, clear cytoplasm, and arborizing vessels, and expressed a TFH immunophenotype (CD3+, CD5+, CD7-, CD4+, strong ICOS, and PD1), though CD25 and FOXP3 were also positive. The FDC meshworks were not expanded, and EBER-CISH was negative. Positive HTLV-1 serology was observed, and HTS characterization of HTLV-1 integration sites disclosed a major clone identical in the LN and blood [84]. Interestingly, an IDH2 R172K variant was identified, questioning whether this could be responsible for the clear cell cytomorphology. However, other characteristic mutations typical of TFHL were not detected.
Others
Other types of lymphoma and lymphoproliferative disorders can mimic TFHL or demonstrate a partial TFH immunophenotype [72]. Case LYWS-1394 (Valentina Tabanelli) was a classic example of a lymphoid variant of hypereosinophilic syndrome (L-HES) in a 51-year-old man with a unilaterally enlarged tonsil and a 13-year history of eosinophilia and an aberrant CD4(+), sCD3(-) T-cell population in the peripheral blood. Aside from isolated tonsil enlargement, the patient was asymptomatic and whole-body PET scan was negative. Identical T-cell immunophenotypes and matching clonal amplicons were identified in the blood, bone marrow, and tonsil, demonstrating near-total effacement by abnormal T-cells expressing partial/weak PD1 and ICOS. CD10, BCL6, and CXCL13 were negative. TFH marker expression is not demonstrated in cases of L-HES and may indicate an evolving sCD3-/CD4+/TFH+ AITL in the differential diagnosis [85, 86]. Despite weak/partial TFH expression in this case, the localized presentation in one tonsil with no microenvironment of a T-cell lymphoma contributed to the panel diagnosis of L-HES rather than TFHL. Finally, abundant reactive TFH cells can occur in various B-cell lymphomas and lymphoproliferative disorders [72, 87]. Examples were case LYWS-1233 (Tanuja Shet) with a variant pattern of nodular lymphocyte predominant B-cell/Hodgkin lymphoma, and case LYWS-1463 (Tiago Maia) with a relapsed EBV-associated polymorphic nodal lymphoproliferative disorder [72, 87].
Reactive or other lymphoproliferations
Several cases were favored to represent reactive lymphoid proliferations of TFH cells (Supplemental Table 4). Case LYWS-1197 (Philip Bulterys, Fig. 10I–L) was a colonic biopsy from a 14-year-old girl known to have an inborn error of immunity due to a mutation in the PIK3CD gene giving rise to activated phosphoinositide 3-kinase Δ syndrome (APDS-1). She presented with chronic stable lymphadenopathy, abdominal pain, and diarrhea. Biopsies showed prominent diffuse lymphoid hyperplasia comprising monotonous small T-lymphocytes expressing CD4, PD1, CXCL13, and ICOS in multiple foci of bowel. Lymphoproliferations of TFH cells in the context of APDS-1 have been previously described [88] including a case report with a similar intestinal nodular lymphoid hyperplasia that resolved after treatment with sirolimus [89]. Carlo Pescia contributed LYWS-1212 involving the sudden onset of oral and lingual aphthous ulceration in a 38-year-old male composed of CD3+ CD4+ PD1+ and frequent CD30+ lymphocytes and eosinophils with a monoclonal TR gene rearrangement that spontaneously regressed; the panel considered this as a form of CD30+ lymphoproliferative disorder most consistent with traumatic ulcerative granuloma with stromal eosinophilia [90] (Fig. 10M and N). This case had only one positive TFH marker, stressing the importance of using multiple TFH markers when assigning TFH lineage and considering the clinical context when entertaining a diagnosis of TFHL. Finally, two submitted cases represented non-specific reactive lymphoid hyperplasia in LN (LYWS-1145 by Tapan Bhavsar and LYWS-1254 by Wen-Qing Yao) with increased numbers of TFH cells as part of a paracortical polymorphic infiltrate or florid follicular hyperplasia.
Conclusions
This spectrum of cases submitted embraced the difficulty in diagnosing TFHL and highlighted notable characteristics of TFH subtypes, as well as reactive and neoplastic mimics (Box 1). The cases reflect the broad differential diagnosis of TFHL and emphasizes the importance of clinical correlation. The final distribution of session V workshop cases had 25 out of 42 cases (60%) being confirmed to as belonging to one of the three follicular helper T-cell lymphoma subtypes (16 AITL-type, 3 TFHL-F, and 6 TFHL-NOS), reflecting the difficulty in assessing the TFH immunophenotype, its lack of specificity, and the need for caution.
Box 1
• A TFH immunophenotype is defined by the expression of a minimum of two TFH markers (of the five recommended for testing, i.e., CD10, BCL6, PD1, ICOS, and CXCL13) in CD4+ T cells • The lower end of the clinicopathologic spectrum of TFHL includes cases with low tumor burden/early involvement and/or pauci-symptomatic, slowly progressive, or indolent disease • Diagnostic difficulties in TFHL include the presence of a B-cell component mimicking cHL, cutaneous T-cell lymphoma expressing TFH markers, and reactive TFH proliferations as part of other lymphoproliferative disorders or benign hyperplasias • TFHL and myeloid neoplasms share an association with underlying CH • Separating TFHL and PTCL, NOS requires understanding the morphologic spectrum of TFHL, demonstrating a strong CD4+/TFH+ immunophenotype, and the presence of certain mutations that are recurrent in TFHL • Needle core biopsies pose a risk to accurate and timely diagnosis of TFHL • Supportive tests including flow cytometry and PCR or genomic testing are helpful in challenging cases especially those with low tumor burden; these contributed to the final diagnosis of 25 cases in this series |
Data availability
This is not applicable.
References
Mintz MA, Cyster JG (2020) T follicular helper cells in germinal center B cell selection and lymphomagenesis. Immunol Rev 296(1):48–61
Grogg KL, Attygalle AD, Macon WR, Remstein ED, Kurtin PJ, Dogan A (2006) Expression of CXCL13, a chemokine highly upregulated in germinal center T-helper cells, distinguishes angioimmunoblastic T-cell lymphoma from peripheral T-cell lymphoma, unspecified. Mod Pathol 19(8):1101–1107
de Leval L, Rickman DS, Thielen C, Reynies A, Huang YL, Delsol G et al (2007) The gene expression profile of nodal peripheral T-cell lymphoma demonstrates a molecular link between angioimmunoblastic T-cell lymphoma (AITL) and follicular helper T (TFH) cells. Blood 109(11):4952–4963
Piccaluga PP, Agostinelli C, Califano A, Carbone A, Fantoni L, Ferrari S et al (2007) Gene expression analysis of angioimmunoblastic lymphoma indicates derivation from T follicular helper cells and vascular endothelial growth factor deregulation. Cancer Res 67(22):10703–10710
Swerdlow SH, Campo E, Harris NL et al (2008) WHO classification of tumours of haematopoietic and lymphoid tissues. IARC Press, Lyon, France
Rodríguez-Pinilla SM, Atienza L, Murillo C, Pérez-Rodríguez A, Montes-Moreno S, Roncador G et al (2008) Peripheral T-cell lymphoma with follicular T-cell markers. Am J Surg Pathol 32(12):1787–1799
Attygalle AD, Chuang SS, Diss TC, Du MQ, Isaacson PG, Dogan A (2007) Distinguishing angioimmunoblastic T-cell lymphoma from peripheral T-cell lymphoma, unspecified, using morphology, immunophenotype and molecular genetics. Histopathology 50(4):498–508
Dobay MP, Lemonnier F, Missiaglia E, Bastard C, Vallois D, Jais JP et al (2017) Integrative clinicopathological and molecular analyses of angioimmunoblastic T-cell lymphoma and other nodal lymphomas of follicular helper T-cell origin. Haematologica 102(4):e148–ee51
Huang Y, Moreau A, Dupuis J, Streubel B, Petit B, Le Gouill S et al (2009) Peripheral T-cell lymphomas with a follicular growth pattern are derived from follicular helper T cells (TFH) and may show overlapping features with angioimmunoblastic T-cell lymphomas. Am J Surg Pathol 33(5):682–690
Iqbal J, Weisenburger DD, Greiner TC, Vose JM, McKeithan T, Kucuk C et al (2010) Molecular signatures to improve diagnosis in peripheral T-cell lymphoma and prognostication in angioimmunoblastic T-cell lymphoma. Blood 115(5):1026–1036
Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R et al (2016) The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood J Am Soc Hematol 127(20):2375–2390
Lemonnier F, Couronné L, Parrens M, Jaïs JP, Travert M, Lamant L et al (2012) Recurrent TET2 mutations in peripheral T-cell lymphomas correlate with TFH-like features and adverse clinical parameters. Blood 120(7):1466–1469
Vallois D, Dobay MP, Morin RD, Lemonnier F, Missiaglia E, Juilland M et al (2016) Activating mutations in genes related to TCR signaling in angioimmunoblastic and other follicular helper T-cell-derived lymphomas. Blood 128(11):1490–1502
Yoon SE, Cho J, Kim YJ, Ko YH, Park WY, Kim SJ et al (2021) Comprehensive analysis of clinical, pathological, and genomic characteristics of follicular helper T-cell derived lymphomas. Exp Hematol Oncol 10(1):33
Campo E, Jaffe ES, Cook JR, Quintanilla-Martinez L, Swerdlow SH, Anderson KC et al (2022) The International Consensus Classification of mature lymphoid neoplasms: a report from the Clinical Advisory Committee. Blood 140(11):1229–1253
Alaggio R, Amador C, Anagnostopoulos I, Attygalle AD, Araujo IBO, Berti E et al (2022) The 5th edition of the World Health Organization classification of haematolymphoid tumours: lymphoid neoplasms. Leukemia 36(7):1720–1748
Frizzera G, Moran EM, Rappaport H (1975) Angio-immunoblastic lymphadenopathy. Diagnosis and clinical course. Am J Med 59(6):803–818
Schmitz N, de Leval L (2017) How I manage peripheral T-cell lymphoma, not otherwise specified and angioimmunoblastic T-cell lymphoma: current practice and a glimpse into the future. Br J Haematol 176(6):851–866
Syrykh C, Chaouat C, Poullot E, Amara N, Fataccioli V, Parrens M et al (2022) Lymph node excisions provide more precise lymphoma diagnoses than core biopsies: a French Lymphopath network survey. Blood 140(24):2573–2583
Jaffe ES, Cook JR (2022) Core biopsy for lymphoma diagnosis? A needling prospect. Blood 140(24):2525–2527
Gonçalves MC, de Oliveira C, Sandes AF, Rodrigues CA, Novis Y, Viana PCC et al (2023) Core needle biopsy in lymphoma diagnosis: the diagnostic performance and the role of the multidisciplinary approach in the optimization of results. Am J Surg Pathol 47(1):111–123
Laurent C, Baron M, Amara N, Haioun C, Dandoit M, Maynadié M et al (2017) Impact of expert pathologic review of lymphoma diagnosis: study of patients from the French lymphopath network. J Clin Oncol 35(18):2008–2017
Cairns RA, Iqbal J, Lemonnier F, Kucuk C, de Leval L, Jais JP et al (2012) IDH2 mutations are frequent in angioimmunoblastic T-cell lymphoma. Blood 119(8):1901–1903
Odejide O, Weigert O, Lane AA, Toscano D, Lunning MA, Kopp N et al (2014) A targeted mutational landscape of angioimmunoblastic T-cell lymphoma. Blood 123(9):1293–1296
Palomero T, Couronné L, Khiabanian H, Kim MY, Ambesi-Impiombato A, Perez-Garcia A et al (2014) Recurrent mutations in epigenetic regulators, RHOA and FYN kinase in peripheral T cell lymphomas. Nat Genet 46(2):166–170
Sakata-Yanagimoto M, Enami T, Yoshida K, Shiraishi Y, Ishii R, Miyake Y et al (2014) Somatic RHOA mutation in angioimmunoblastic T cell lymphoma. Nat Genet 46(2):171–175
de Leval L, Gisselbrecht C, Gaulard P (2010) Advances in the understanding and management of angioimmunoblastic T-cell lymphoma. Br J Haematol 148(5):673–689
Mourad N, Mounier N, Brière J, Raffoux E, Delmer A, Feller A et al (2008) Clinical, biologic, and pathologic features in 157 patients with angioimmunoblastic T-cell lymphoma treated within the Groupe d'Etude des Lymphomes de l’Adulte (GELA) trials. Blood 111(9):4463–4470
Lachenal F, Berger F, Ghesquières H, Biron P, Hot A, Callet-Bauchu E et al (2007) Angioimmunoblastic T-cell lymphoma: clinical and laboratory features at diagnosis in 77 patients. Medicine (Baltimore) 86(5):282–292
Federico M, Rudiger T, Bellei M, Nathwani BN, Luminari S, Coiffier B et al (2013) Clinicopathologic characteristics of angioimmunoblastic T-cell lymphoma: analysis of the international peripheral T-cell lymphoma project. J Clin Oncol 31(2):240–246
Xie Y, Jaffe ES (2021) How I diagnose angioimmunoblastic T-cell lymphoma. Am J Clin Pathol 156(1):1–14
de Leval L, Gaulard P (2008) Pathobiology and molecular profiling of peripheral T-cell lymphomas. Hematol Am Soc Hematol Educ Program 2008:272–9
Attygalle A, Al-Jehani R, Diss TC, Munson P, Liu H, Du MQ et al (2002) Neoplastic T cells in angioimmunoblastic T-cell lymphoma express CD10. Blood 99(2):627–633
Attygalle AD, Kyriakou C, Dupuis J, Grogg KL, Diss TC, Wotherspoon AC et al (2007) Histologic evolution of angioimmunoblastic T-cell lymphoma in consecutive biopsies: clinical correlation and insights into natural history and disease progression. Am J Surg Pathol 31(7):1077–1088
Ondrejka SL, Grzywacz B, Bodo J, Makishima H, Polprasert C, Said JW et al (2016) Angioimmunoblastic T-cell lymphomas with the RHOA p.Gly17Val mutation have classic clinical and pathologic features. Am J Surg Pathol 40(3):335–341
Basha BM, Bryant SC, Rech KL, Feldman AL, Vrana JA, Shi M et al (2019) Application of a 5 Marker panel to the routine diagnosis of peripheral T-cell lymphoma with T-follicular helper phenotype. Am J Surg Pathol 43(9):1282–1290
Margolskee E, Jobanputra V, Jain P, Chen J, Ganapathi K, Nahum O et al (2016) Genetic landscape of T- and NK-cell post-transplant lymphoproliferative disorders. Oncotarget 7(25):37636–37648
de Leval L, Savilo E, Longtine J, Ferry JA, Harris NL (2001) Peripheral T-cell lymphoma with follicular involvement and a CD4+/bcl-6+ phenotype. Am J Surg Pathol 25(3):395–400
Ikonomou IM, Tierens A, Troen G, Aamot HV, Heim S, Lauritzsen GF et al (2006) Peripheral T-cell lymphoma with involvement of the expanded mantle zone. Virchows Arch 449(1):78–87
Streubel B, Vinatzer U, Willheim M, Raderer M, Chott A (2006) Novel t(5;9)(q33;q22) fuses ITK to SYK in unspecified peripheral T-cell lymphoma. Leukemia 20(2):313–318
Miyoshi H, Sakata-Yanagimoto M, Shimono J, Yoshida N, Hattori K, Arakawa F et al (2020) RHOA mutation in follicular T-cell lymphoma: clinicopathological analysis of 16 cases. Pathol Int 70(9):653–660
Nicolae A, Pittaluga S, Venkataraman G, Vijnovich-Baron A, Xi L, Raffeld M et al (2013) Peripheral T-cell lymphomas of follicular T-helper cell derivation with Hodgkin/Reed-Sternberg cells of B-cell lineage: both EBV-positive and EBV-negative variants exist. Am J Surg Pathol 37(6):816–826
Alikhan M, Song JY, Sohani AR, Moroch J, Plonquet A, Duffield AS et al (2016) Peripheral T-cell lymphomas of follicular helper T-cell type frequently display an aberrant CD3(-/dim)CD4(+) population by flow cytometry: an important clue to the diagnosis of a Hodgkin lymphoma mimic. Mod Pathol 29(10):1173–1182
Hartmann S, Goncharova O, Portyanko A, Sabattini E, Meinel J, Küppers R et al (2019) CD30 expression in neoplastic T cells of follicular T cell lymphoma is a helpful diagnostic tool in the differential diagnosis of Hodgkin lymphoma. Mod Pathol 32(1):37–47
Miyoshi H, Sato K, Niino D, Arakawa F, Kimura Y, Kiyasu J et al (2012) Clinicopathologic analysis of peripheral T-cell lymphoma, follicular variant, and comparison with angioimmunoblastic T-cell lymphoma: Bcl-6 expression might affect progression between these disorders. Am J Clin Pathol 137(6):879–889
Yoon SE, Song Y, Kim SJ, Yoon DH, Chen TY, Koh Y et al (2021) Comprehensive analysis of peripheral T-cell and natural killer/T-cell lymphoma in Asian patients: a multinational, multicenter, prospective registry study in Asia. Lancet Reg Health West Pac 10:100126
Hartmann S, Agostinelli C, Klapper W, Korkolopoulou P, Koch K, Marafioti T et al (2011) Revising the historical collection of epithelioid cell-rich lymphomas of the Kiel Lymph Node Registry: what is Lennert's lymphoma nowadays? Histopathology 59(6):1173–1182
Moroch J, Copie-Bergman C, de Leval L, Plonquet A, Martin-Garcia N, Delfau-Larue MH et al (2012) Follicular peripheral T-cell lymphoma expands the spectrum of classical Hodgkin lymphoma mimics. Am J Surg Pathol 36(11):1636–1646
Huppmann AR, Roullet MR, Raffeld M, Jaffe ES (2013) Angioimmunoblastic T-cell lymphoma partially obscured by an Epstein-Barr virus-negative clonal plasma cell proliferation. J Clin Oncol 31(2):e28–e30
Kaffenberger B, Haverkos B, Tyler K, Wong HK, Porcu P, Gru AA (2015) Extranodal marginal zone lymphoma-like presentations of angioimmunoblastic T-cell lymphoma: a T-cell lymphoma masquerading as a B-cell lymphoproliferative disorder. Am J Dermatopathol 37(8):604–613
Yamane A, Awaya N, Shimizu T, Ikeda Y, Okamoto S (2007) Angioimmunoblastic T-cell lymphoma with polyclonal proliferation of plasma cells in peripheral blood and marrow. Acta Haematol 117(2):74–77
Smith JL, Hodges E, Quin CT, McCarthy KP, Wright DH (2000) Frequent T and B cell oligoclones in histologically and immunophenotypically characterized angioimmunoblastic lymphadenopathy. Am J Pathol 156(2):661–669
Tan BT, Warnke RA, Arber DA (2006) The frequency of B- and T-cell gene rearrangements and epstein-barr virus in T-cell lymphomas: a comparison between angioimmunoblastic T-cell lymphoma and peripheral T-cell lymphoma, unspecified with and without associated B-cell proliferations. J Mol Diagn 8(4):466–475
Balagué O, Martínez A, Colomo L, Roselló E, Garcia A, Martínez-Bernal M et al (2007) Epstein-Barr virus negative clonal plasma cell proliferations and lymphomas in peripheral T-cell lymphomas: a phenomenon with distinctive clinicopathologic features. Am J Surg Pathol 31(9):1310–1322
Couronné L, Bastard C, Bernard OA (2012) TET2 and DNMT3A mutations in human T-cell lymphoma. N Engl J Med 366(1):95–96
Tiacci E, Venanzi A, Ascani S, Marra A, Cardinali V, Martino G et al (2018) High-risk clonal hematopoiesis as the origin of AITL and NPM1-mutated AML. N Engl J Med 379(10):981–984
Kommalapati A, Tella SH, Go RS, Bennani NN, Goyal G (2019) A population-based analysis of second primary malignancies in T-cell neoplasms. Br J Haematol 185(2):338–342
Lewis NE, Petrova-Drus K, Huet S, Epstein-Peterson ZD, Gao Q, Sigler AE et al (2020) Clonal hematopoiesis in angioimmunoblastic T-cell lymphoma with divergent evolution to myeloid neoplasms. Blood Adv 4(10):2261–2271
Yao WQ, Wu F, Zhang W, Chuang SS, Thompson JS, Chen Z et al (2020) Angioimmunoblastic T-cell lymphoma contains multiple clonal T-cell populations derived from a common TET2 mutant progenitor cell. J Pathol 250(3):346–357
Quivoron C, Couronné L, Della Valle V, Lopez CK, Plo I, Wagner-Ballon O et al (2011) TET2 inactivation results in pleiotropic hematopoietic abnormalities in mouse and is a recurrent event during human lymphomagenesis. Cancer Cell 20(1):25–38
Nguyen TB, Sakata-Yanagimoto M, Asabe Y, Matsubara D, Kano J, Yoshida K et al (2017) Identification of cell-type-specific mutations in nodal T-cell lymphomas. Blood Cancer J 7(1):e516
Schwartz FH, Cai Q, Fellmann E, Hartmann S, Mäyränpää MI, Karjalainen-Lindsberg ML et al (2017) TET2 mutations in B cells of patients affected by angioimmunoblastic T-cell lymphoma. J Pathol 242(2):129–133
Iqbal J, Wright G, Wang C, Rosenwald A, Gascoyne RD, Weisenburger DD et al (2014) Gene expression signatures delineate biological and prognostic subgroups in peripheral T-cell lymphoma. Blood 123(19):2915–2923
Heavican TB, Bouska A, Yu J, Lone W, Amador C, Gong Q et al (2019) Genetic drivers of oncogenic pathways in molecular subgroups of peripheral T-cell lymphoma. Blood 133(15):1664–1676
Amador C, Greiner TC, Heavican TB, Smith LM, Galvis KT, Lone W et al (2019) Reproducing the molecular subclassification of peripheral T-cell lymphoma-NOS by immunohistochemistry. Blood 134(24):2159–2170
Patsouris E, Noël H, Lennert K (1988) Histological and immunohistological findings in lymphoepithelioid cell lymphoma (Lennert's lymphoma). Am J Surg Pathol 12(5):341–350
Geissinger E, Odenwald T, Lee SS, Bonzheim I, Roth S, Reimer P et al (2004) Nodal peripheral T-cell lymphomas and, in particular, their lymphoepithelioid (Lennert’s) variant are often derived from CD8(+) cytotoxic T-cells. Virchows Arch 445(4):334–343
Patsouris E, Noël H, Lennert K (1989) Angioimmunoblastic lymphadenopathy-type of T-cell Lymphoma with a high content of epithelioid cells: histopathology and comparison with lymphoepithelioid cell lymphoma. Am J Surg Pathol 13(4):262
Weisenburger DD, Savage KJ, Harris NL, Gascoyne RD, Jaffe ES, MacLennan KA et al (2011) Peripheral T-cell lymphoma, not otherwise specified: a report of 340 cases from the International Peripheral T-cell Lymphoma Project. Blood 117(12):3402–3408
Kurita D, Miyoshi H, Yoshida N, Sasaki Y, Kato S, Niino D et al (2016) A clinicopathologic study of Lennert lymphoma and possible prognostic factors: the importance of follicular helper T-cell markers and the association with angioimmunoblastic T-cell lymphoma. Am J Surg Pathol 40(9):1249–1260
Agostinelli C, Hartmann S, Klapper W, Korkolopoulou P, Righi S, Marafioti T et al (2011) Peripheral T cell lymphomas with follicular T helper phenotype: a new basket or a distinct entity? Revising Karl Lennert's personal archive. Histopathology 59(4):679–691
Abukhiran I, Syrbu SI, Holman CJ (2021) Markers of Follicular Helper T Cells Are Occasionally Expressed in T-cell or histiocyte-rich large B-cell lymphoma, classic Hodgkin lymphoma, and atypical paracortical hyperplasiaa diagnostic pitfall for T-cell lymphomas of T follicular helper origin. Am J Clin Pathol 156(3):409–426
Piccaluga PP, Fuligni F, De Leo A, Bertuzzi C, Rossi M, Bacci F et al (2013) Molecular profiling improves classification and prognostication of nodal peripheral T-cell lymphomas: results of a phase III diagnostic accuracy study. J Clin Oncol 31(24):3019–3025
Nicolae A, Bouilly J, Lara D, Fataccioli V, Lemonnier F, Drieux F et al (2022) Nodal cytotoxic peripheral T-cell lymphoma occurs frequently in the clinical setting of immunodysregulation and is associated with recurrent epigenetic alterations. Mod Pathol 35(8):1126–1136
Herek TA, Bouska A, Lone W, Sharma S, Amador C, Heavican TB et al (2022) DNMT3A mutations define a unique biological and prognostic subgroup associated with cytotoxic T cells in PTCL-NOS. Blood 140(11):1278–1290
de Leval L, Alizadeh AA, Bergsagel PL, Campo E, Davies A, Dogan A et al (2022) Genomic profiling for clinical decision making in lymphoid neoplasms. Blood 140(21):2193–2227
Sethi TK, Montanari F, Foss F, Reddy N (2021) How we treat advanced stage cutaneous T-cell lymphoma - mycosis fungoides and Sezary syndrome. Br J Haematol 195(3):352–364
Meyerson HJ, Awadallah A, Pavlidakey P, Cooper K, Honda K, Miedler J (2013) Follicular center helper T-cell (TFH) marker positive mycosis fungoides/Sezary syndrome. Mod Pathol 26(1):32–43
Bosisio FM, Cerroni L (2015) Expression of T-follicular helper markers in sequential biopsies of progressive mycosis fungoides and other primary cutaneous T-cell lymphomas. Am J Dermatopathol 37(2):115–121
Leclaire Alirkilicarslan A, Dupuy A, Pujals A, Parrens M, Vergier B, Robson A et al (2017) Expression of TFH markers and detection of RHOA p.G17V and IDH2 p.R172K/S mutations in cutaneous localizations of angioimmunoblastic T-cell lymphomas. Am J Surg Pathol 41(12):1581–1592
Chavan RN, Bridges AG, Knudson RA, Ketterling RP, Comfere N, Wada DA et al (2014) Somatic rearrangement of the TP63 gene preceding development of mycosis fungoides with aggressive clinical course. Blood Cancer J 4(10):e253
Vasmatzis G, Johnson SH, Knudson RA, Ketterling RP, Braggio E, Fonseca R et al (2012) Genome-wide analysis reveals recurrent structural abnormalities of TP63 and other p53-related genes in peripheral T-cell lymphomas. Blood 120(11):2280–2289
Karube K, Suzumiya J, Okamoto M, Takeshita M, Maeda K, Sakaguchi M et al (2007) Adult T-cell lymphoma/leukemia with angioimmunoblastic T-cell lymphomalike features: Report of 11 cases. Am J Surg Pathol 31(2):216–223
Marçais A, Lhermitte L, Artesi M, Laurent C, Durkin K, Hahaut V et al (2021) Targeted deep sequencing reveals clonal and subclonal mutational signatures in adult T-cell leukemia/lymphoma and defines an unfavorable indolent subtype. Leukemia 35(3):764–776
Lefèvre G, Copin MC, Roumier C, Aubert H, Avenel-Audran M, Grardel N et al (2015) CD3-CD4+ lymphoid variant of hypereosinophilic syndrome: nodal and extranodal histopathological and immunophenotypic features of a peripheral indolent clonal T-cell lymphoproliferative disorder. Haematologica 100(8):1086–1095
King RL, Tan B, Craig FE, George TI, Horny H-P, Kelemen K et al (2020) Reactive eosinophil proliferations in tissue and the lymphocytic variant of hypereosinophilic syndrome: 2019 Society for Hematopathology/European Association for Haematopathology Workshop Report. Am J Clin Pathol 155(2):211–238
Egan C, Laurent C, Alejo JC, Pileri S, Campo E, Swerdlow SH et al (2020) Expansion of PD1-positive T cells in nodal marginal zone lymphoma: a potential diagnostic pitfall. Am J Surg Pathol 44(5):657–664
Coulter TI, Chandra A, Bacon CM, Babar J, Curtis J, Screaton N et al (2017) Clinical spectrum and features of activated phosphoinositide 3-kinase δ syndrome: a large patient cohort study. J Allergy Clin Immunol 139(2):597–606.e4
Marzollo A, Bresolin S, Colavito D, Cani A, Gaio P, Bosa L et al (2021) Case report: intestinal nodular lymphoid hyperplasia as first manifestation of activated PI3Kδ syndrome due to a novel PIK3CD variant. Front Pediatr 9:703056
Hirshberg A, Amariglio N, Akrish S, Yahalom R, Rosenbaum H, Okon E et al (2006) Traumatic ulcerative granuloma with stromal eosinophilia: a reactive lesion of the oral mucosa. Am J Clin Pathol 126(4):522–529
Drieux F, Ruminy P, Sater V, Marchand V, Fataccioli V, Lanic MD et al (2021) Detection of Gene fusion transcripts in peripheral T-cell lymphoma using a multiplexed targeted sequencing assay. J Mol Diagn 23(8):929–940
Acknowledgements
The authors thank the workshop participants who submitted cases to this session, for their contributions, for providing the additional information requested and for allowing us to use the case images in this review. The authors thank Bettina Bisig, Baptiste Guey, and Edoardo Missiaglia from the University Institute of Pathology in Lausanne, for performing the HTS analyses in the cases submitted to the workshop. We also thank Nathalie Piazzon and Melanie Metrich from the Laboratory of Immunopathology and Jean-Daniel Roman from the Digital Imaging platform, all from the University Institute of Pathology in Lausanne for supporting us with the organization of this session, performing additional immunostainings, and digitalizing the histological slides of the workshop.
Funding
Open access funding provided by University of Lausanne. L. de L. acknowledges funding by the Swiss National Science Foundation (SNSF)(grant number 310030_172954). S-B.N is supported by the National Medical Research Council Senior Investigator Clinician Scientist Award (MOH-001104).
Author information
Authors and Affiliations
Contributions
S.L.O., C.A., and L. de L. reviewed all the cases, validated the final diagnoses, designed the analysis of the cases, and wrote the manuscript. All authors participated in the case review and discussion, concurred with the diagnoses, and have read and agree with the content of this manuscript.
Corresponding author
Ethics declarations
Conflict of interest
The authors declare no competing interests.
Additional information
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary information
ESM 1
(XLSX 100 kb)
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Ondrejka, S.L., Amador, C., Climent, F. et al. Follicular helper T-cell lymphomas: disease spectrum, relationship with clonal hematopoiesis, and mimics. A report of the 2022 EA4HP/SH lymphoma workshop. Virchows Arch 483, 349–365 (2023). https://doi.org/10.1007/s00428-023-03607-5
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00428-023-03607-5